Subsequently, a trial of 61 patients with influenza A (H7N9)-induced ARDS showed significant reduction in the inflammatory marker CRP following menstrual-blood-derived MSC treatment, compared to placebo (163). This evidence concerns the gene CRP and acute respiratory distress syndrome.